2 results
Approved WMOCompleted
In this study, the main clinical hypothesis is that the TIMI clinically significant bleeding rates will not be different between the rivaroxaban and VKA treatment strategy groups at Month 12.
Approved WMOCompleted
Primary: To collect long-term safety data.Secondary objectives: To collect long-term efficacy data (LDL-C).